Boehringer’s Next Gen Protease Inhibitor Potent In Tough-to-Treat Hep C Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II data presented at the American Association for the Study of Liver Disease meeting on BI 201335 support efficacy in hard to treat genetic subtypes and with shorter treatment periods.
You may also be interested in...
Boehringer Ingelheim's Phase II Agent Could Be The First Second-Wave Protease Inhibitor For Hep C
BI's '355 has impressive response rates in early studies, but jaundice is a concern.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.